Evidence map›Paper›PMID 37755642›Full record

ArticleInternational journal of clinical pharmacy2023

Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health.

Matej Stuhec, M Hahn, I Taskova, I Bayraktar, I Fitzgerald, L Molitschnig, A Tatarević, N Lindner, L Agnoletto, F Alves da Costa

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 4 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Observational
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 7 countries.

Matej StuhecDepartment of Pharmacology, Faculty of Medicine Maribor, University of Maribor, Maribor, Slovenia. matejstuhec@gmail.com.ORCID http://orcid.org/0000-0001-5909-6930
M HahnDepartment of Mental Health, Varisano Hospital Frankfurt Hoechst, Frankfurt, Germany.
I TaskovaPsychiatric Hospital Bohnice, Prague, Czech Republic.
I BayraktarDepartment of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
I FitzgeraldPharmacy Department, St Patrick's University Hospital, Dublin 8, Ireland.
L MolitschnigPharmacy Department, Hospital of Elisabethians, Graz, Austria.
A TatarevićPharmacy Bobanović Vujnović, Pula, Croatia.
N LindnerPharmacy Department, Vienna General Hospital-Medical University Campus, Vienna, Austria.
L AgnolettoHospital Pharmacy, Rovigo Hospital, Rovigo, Italy.
F Alves da CostaResearch Institute for Medicines, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
Goethe University Frankfurt · DEHacettepe University · TRKrankenhaus der Elisabethinen · ATMasaryk University · CZUniversity College Cork · IEUniversity of Lisbon · PTUniversity of Maribor · SIVienna General Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A large proportion of the world's disease burden is attributable to mental illnesses. Although effective interventions are available, many patients still have limited access to evidence-based treatments. Aside from access, treatment gaps, including inappropriate medication selection and monitoring, are also routinely recognised. Mental health clinical pharmacists can help address these gaps and enable patients to receive optimised pharmaceutical care, particularly appropriate medication selection and monitoring. The European Society of Clinical Pharmacy (ESCP) Special Interest Group on Mental Health was established to improve standardised service provision in mental health settings across Europe. The Special Interest Group identified significant barriers (predominantly associated with reimbursement and position within the multidisciplinary team) to effective pharmaceutical care amongst those with mental illnesses. This commentary presents recommendations to address these gaps through improved mental health clinical pharmacy service provision.

Indexed as

PharmacyPharmacy Service, HospitalEuropeHumansMental HealthPharmacistsPublic OpinionClinical pharmacist interventionsClinical pharmacy in mental healthEuropean society of clinical pharmacyMental illnesses and pharmacyPharmaceutical services in mental healthPolypharmacy and clinical pharmacyPsychotropics and clinical pharmacy

Identifiers

PMID37755642
PMCPMC10600282
OpenAlexW4387077170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.